Trials / Completed
CompletedNCT00219986
Phase I/II, Open-Label Trial of Three Monoclonal Antibodies
A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- Rockefeller University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Potent HAART during acute or early HIV-1 infection |
Timeline
- Start date
- 2003-10-01
- Completion
- 2005-09-01
- First posted
- 2005-09-22
- Last updated
- 2007-07-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00219986. Inclusion in this directory is not an endorsement.